Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

Item
http://www.wikidata.org/entity/Q37272164
JAK2 inhibitors for myeloproliferative neoplasms: what is next?New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis.Evaluation of Short-Term Ruxolitinib Tapering Strategy Before Allogeneic Stem Cell Transplantation for Primary Myelofibrosis Through the Transition of Serum Cytokines and Growth Factors.Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.Atypical chronic myeloid leukemia: a rare entity with management challenges.Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
P2860

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

Item
http://www.wikidata.org/entity/Q37272164
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 October 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Outcomes of Allogeneic Hematop ...... o Janus Kinase 1/2 Inhibitors.
@en
Outcomes of Allogeneic Hematop ...... o Janus Kinase 1/2 Inhibitors.
@nl
type
label
Outcomes of Allogeneic Hematop ...... o Janus Kinase 1/2 Inhibitors.
@en
Outcomes of Allogeneic Hematop ...... o Janus Kinase 1/2 Inhibitors.
@nl
prefLabel
Outcomes of Allogeneic Hematop ...... o Janus Kinase 1/2 Inhibitors.
@en
Outcomes of Allogeneic Hematop ...... o Janus Kinase 1/2 Inhibitors.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Outcomes of Allogeneic Hematop ...... to Janus Kinase 1/2 Inhibitors
@en
P2093
P2860
P304
P31
P356
10.1016/J.BBMT.2015.10.005
P433
P478
P50
P577
P698
P932